Clinical Trials Logo

Clinical Trial Summary

This is an international multicenter, open-label, randomized phase III trial including three sequential randomizations to assess efficacy of induction and consolidation chemotherapies and radiotherapy for patients with high-risk neuroblastoma.


Clinical Trial Description

This is an international multicenter, open-label, randomized phase III trial including three sequential randomizations to assess efficacy of induction and consolidation chemotherapies and radiotherapy for patients with high-risk neuroblastoma. The first randomization (R-I) will compare the efficacy of two induction chemotherapies (RAPID COJEC and GPOH regimens) in a phase III setting. The primary endpoint will be the 3-year EFS from date of randomization . The R-I randomization will be stratified on age, stage, MYCN status and countries. The second randomization (R-HDC) will compare the efficacy of single HDC with Bu-Mel versus tandem HDC with Thiotepa followed by Bu-Mel. The primary endpoint is 3-year EFS calculated from the date of the R-HDC randomization. The R-HDC randomization will be stratified on the age, stage, MYCN status, induction chemotherapy regimen, response to induction phase and countries. The impact of local treatment in this phase III setting will be assessed, according to the presence or not of a macroscopic residual disease after surgery and HDC. In case of macroscopic residual disease, 21.6 Gy radiotherapy to the preoperative tumor bed will be randomized (R-RTx) versus the same treatment plus a sequential boost of additional 14.4 Gy to the residual tumor. The primary endpoint of R-RTx is 3-year EFS from the date of the R-RTx randomization. The R-RTx randomization will be stratified on age, stage, MYCN status, induction chemotherapy regimen, HDC regimen and countries. In case of no macroscopic residual disease, 21.6 Gy radiotherapy will be delivered to the preoperative tumor bed. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04221035
Study type Interventional
Source Gustave Roussy, Cancer Campus, Grand Paris
Contact Claudia Pasqualini, MD PhD
Phone +33 (0)1 42 11 42 11
Email claudia.pasqualini@gustaveroussy.fr
Status Recruiting
Phase Phase 3
Start date November 5, 2019
Completion date November 2032

See also
  Status Clinical Trial Phase
Recruiting NCT06057948 - A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma Phase 2
Not yet recruiting NCT06335745 - PediCARE Health Equity Intervention in High-Risk Neuroblastoma N/A
Recruiting NCT05489887 - Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma Phase 2
Recruiting NCT05650749 - GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma Phase 1
Completed NCT05373901 - Evaluation of the Safety and Pharmacokinetics of Dinutuximab Beta as Maintenance Therapy in Chinese Patients With High-risk Neuroblastoma Phase 1
Not yet recruiting NCT06182410 - Defibrotide Prophylaxis of Transplant Associated-Thrombotic Microangiopathy for Neuroblastoma Phase 2
Recruiting NCT05272371 - Immunotherapy With Dinutuximab Beta in Combination With Chemotherapy for the Treatment of Patients With Primary Neuroblastoma Refractory to Standard Therapy and With Relapsed or Progressive Disease Phase 1
No longer available NCT04501757 - Naxitamab and GM-CSF in People With Neuroblastoma